Search
Now showing items 1-10 of 12
-
Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity
(HighWire, 2020-03-10)As a prototype of genomics-guided precision medicine, individualized thiopurine dosing based on pharmacogenetics is a highly effective way to mitigate hematopoietic toxicity of this class of drugs. Recently, NUDT15 deficiency ... -
Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study
(BMJ, 2020-10)Objective: To determine the diagnostic accuracy of calprotectin to diagnose inflammatory bowel disease (IBD) in children in whom general practitioners (GPs) suspected IBD. Design: Prospective observational cohort study ... -
Clinical features and genetic risk of demyelination following anti-TNF treatment
(Silverchair Information Systems, 2020-06-04)Background: Anti-TNF exposure has been linked to demyelination events. We sought to describe the clinical features of demyelination events following anti-TNF treatment and test whether affected patients were genetically ... -
HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's Disease
(Elsevier, 2020-01)Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologic drugs for treating immune-mediated diseases, but repeated administration can induce the formation of anti-drug antibodies. The ability to ... -
OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
(Oxford University Press, 2020-01-15)Background Anti-drug antibodies can affect biopharmaceutical pharmacokinetics by increasing or decreasing drug clearance. Drug-tolerant (total), unlike drug-sensitive (free), antibody assays permit antibodies to be measured ... -
DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohn’s disease: A pilot serum proteomic analysis of the PANTS cohort
(Oxford University Press, 2020-01-15)Background Proteomic biomarkers have been linked to anti-TNF treatment failure, but previous studies have been insufficiently powered to stratify associations by drug level. The Personalised Anti-TNF Therapy in Crohn’s ... -
DOP69 Tofacitinib in ulcerative colitis: Early ‘real-world’ experience from four UK tertiary centres
(Oxford University Press, 2020-01-15)Background Tofacitinib is a partially selective Janus kinase inhibitor that was approved for the treatment of refractory moderate to severe ulcerative colitis (UC) in 2018. We report the real-world clinical effectiveness ... -
P208 Correlation between physician and patient disease assessments in ulcerative colitis: 2-year UK data from the ICONIC study
(Oxford University Press, 2020-01-15)Background ICONIC is the largest prospective multi-country (n = 33) observational study assessing burden in adult ulcerative colitis (UC) patients under routine care. Both patient and physician assessments of disease ... -
Quality improvement project identifies factors associated with delay in IBD diagnosis
(Wiley, 2020-08)Background: Delay in the diagnosis of inflammatory bowel disease (IBD) is common and contemporary UK studies are lacking. Aim: To determine factors associated with, and the consequences of, a prolonged time to diagnosis ... -
Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience
(Oxford University Press, 2020-04-13)Background: Tofacitinib is a partially selective Janus kinase inhibitor approved for the treatment of refractory moderate to severe ulcerative colitis (UC). We sought to define the effectiveness and adverse effects of ...